DK0584185T3 - Behandling af træthedssyndrom med cholinesteraseinhibitorer - Google Patents

Behandling af træthedssyndrom med cholinesteraseinhibitorer

Info

Publication number
DK0584185T3
DK0584185T3 DK92910754T DK92910754T DK0584185T3 DK 0584185 T3 DK0584185 T3 DK 0584185T3 DK 92910754 T DK92910754 T DK 92910754T DK 92910754 T DK92910754 T DK 92910754T DK 0584185 T3 DK0584185 T3 DK 0584185T3
Authority
DK
Denmark
Prior art keywords
cholinesterase
schizophrenia
treatment
benzodiazepines
anxiety
Prior art date
Application number
DK92910754T
Other languages
English (en)
Inventor
Ernir Snorrason
Original Assignee
Ernir Snorrason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IS3706A external-priority patent/IS3706A7/is
Priority claimed from DK18192A external-priority patent/DK18192D0/da
Application filed by Ernir Snorrason filed Critical Ernir Snorrason
Application granted granted Critical
Publication of DK0584185T3 publication Critical patent/DK0584185T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Transceivers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK92910754T 1991-05-14 1992-05-14 Behandling af træthedssyndrom med cholinesteraseinhibitorer DK0584185T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS3706A IS3706A7 (is) 1991-05-14 1991-05-14 Notkun á galantamine-hydróbrómíði í geðlæknisfræði
DK18192A DK18192D0 (da) 1992-02-13 1992-02-13 Method of treating chronic fatigue syndrome
PCT/DK1992/000160 WO1992020327A1 (en) 1991-05-14 1992-05-14 Treatment of fatigue syndrome with cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
DK0584185T3 true DK0584185T3 (da) 2000-02-07

Family

ID=36886660

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92910754T DK0584185T3 (da) 1991-05-14 1992-05-14 Behandling af træthedssyndrom med cholinesteraseinhibitorer

Country Status (13)

Country Link
US (1) US5312817A (da)
EP (2) EP0515301A3 (da)
JP (1) JP3291730B2 (da)
AT (1) ATE183084T1 (da)
CA (1) CA2108880A1 (da)
DE (1) DE69229781T2 (da)
DK (1) DK0584185T3 (da)
ES (1) ES2134215T3 (da)
GR (1) GR3031559T3 (da)
IE (1) IE921547A1 (da)
NO (1) NO307078B1 (da)
NZ (1) NZ242744A (da)
WO (1) WO1992020327A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE215079T1 (de) * 1992-07-24 2002-04-15 Univ California Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5585375A (en) * 1994-07-01 1996-12-17 Davis; Bonnie M. Method for alleviating jet lag
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
DE19533772C1 (de) * 1995-09-12 1998-01-02 Hexal Ag Tacrin/Selegilin-Pflaster
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6399622B1 (en) 1997-02-18 2002-06-04 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6537997B1 (en) 1997-02-18 2003-03-25 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US5872123A (en) 1997-02-18 1999-02-16 Lerner; A. Martin Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US20020177593A1 (en) 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
EP1118322A4 (en) * 1998-09-30 2004-10-20 Takeda Chemical Industries Ltd MEDICINES FOR IMPROVING BUBBLE EMPTYING STRENGTH
PL348107A1 (en) * 1998-10-16 2002-05-06 Janssen Pharmaceutica Nv Therapy for improving cognition
KR100437105B1 (ko) * 1998-12-24 2004-06-23 얀센 파마슈티카 엔.브이. 방출 조절형 갈란타민 조성물
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
ATE355066T1 (de) * 1999-01-11 2006-03-15 Atanas Russinov Djananov Nahrungszusatz aus kräutern zur steigerung der muskulären kraft und ausdauer von athleten
EP1237524A4 (en) 1999-12-10 2004-06-30 Bonnie M Davis GALANTHAMINE AND LYCORAMINE ANALOGS FOR USE AS MODULATORS OF NICOTINIC RECEPTORS
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
US6825177B2 (en) * 2000-10-30 2004-11-30 Parker Hughes Institute Aryl phosphate derivatives of d4T with potent anti-viral activity
EP1603595B1 (en) * 2003-02-27 2010-11-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
WO2005016327A2 (en) * 2003-08-13 2005-02-24 Janssen Pharmaceutica, N.V. Treatment of sleep disorders with cholinesterase inhibitors
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
US9186345B2 (en) 2004-10-12 2015-11-17 Hakon Hakonarson Method of treating skin diseases
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP2019679B1 (en) 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
JP5583003B2 (ja) 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
CA2697349C (en) 2007-08-23 2012-04-24 Theracos, Inc. Benzylbenzene derivatives and methods of use
EP2312944B1 (en) 2008-07-15 2018-09-05 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
ES2599330T3 (es) 2008-08-22 2017-02-01 Theracos Sub, Llc Proceso para la preparación de inhibidores de SGLT2
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
WO2010123184A1 (ko) * 2009-04-24 2010-10-28 제주대학교 산학협력단 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물
US8846909B2 (en) 2010-05-24 2014-09-30 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2675893B1 (en) 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
US20140100238A1 (en) 2012-10-04 2014-04-10 Ohio State University Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3221827A1 (de) * 1982-06-09 1983-12-15 DSO Pharmachim, Sofija Biostimulierendes mittel
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
JP2755403B2 (ja) * 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物

Also Published As

Publication number Publication date
NO307078B1 (no) 2000-02-07
EP0515301A3 (en) 1993-06-16
IE921547A1 (en) 1992-11-18
DE69229781T2 (de) 2000-01-05
ATE183084T1 (de) 1999-08-15
AU1886392A (en) 1992-12-30
JP3291730B2 (ja) 2002-06-10
EP0515301A2 (en) 1992-11-25
CA2108880A1 (en) 1992-11-15
DE69229781D1 (de) 1999-09-16
NZ242744A (en) 1997-02-24
NO934104D0 (no) 1993-11-12
EP0584185A1 (en) 1994-03-02
EP0584185B1 (en) 1999-08-11
NO934104L (no) 1993-11-12
WO1992020327A1 (en) 1992-11-26
AU658424B2 (en) 1995-04-13
ES2134215T3 (es) 1999-10-01
US5312817A (en) 1994-05-17
GR3031559T3 (en) 2000-01-31
JPH06507617A (ja) 1994-09-01

Similar Documents

Publication Publication Date Title
DK0584185T3 (da) Behandling af træthedssyndrom med cholinesteraseinhibitorer
NO934103L (no) Forbedringer i benzodiazepin-behandling med cholinesterase- inhibitorer
MY140557A (en) Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
AR008853A1 (es) Nuevos compuestos farmaceuticamente activos, su uso en la fabricacion de medicamentos, metodo de tratamiento, composicion farmaceutica, compuestosintermediarios y proceso para la fabricacion de dichos compuestos
AR016453A1 (es) Pirazolopirimidinas y perazolotriazinas, un procedimiento para su preparacion, medicamentos y el uso de las mismas para la elaboracion de los medicamentos
PA8491901A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
ATE257156T1 (de) (1,2,4)triazolo(1,5-c)pyrimidin-derivate
AR051395A1 (es) Derivados de imidazo- benzodiazepina, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos, y usos en terapeutica
GB9921150D0 (en) Therapeutic agents
PT912184E (pt) Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
HK1116184A1 (en) Halogenated pyrazolo [1,5-a]pyrimidines, processes, uses as gaba-a receptors ligand, compositions and intermediates
HUP0002650A2 (hu) 4-Oxo-3,5-dihidro-4H-piridazino[4,5-b]-indol-1-acetamid-származékok, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
DK1023291T3 (da) Dipyridoimidazolderivater, som er egnet til behandling af lidelser i centralnervesystemet
NO20021041L (no) Polymorfismer av N-metyl-N-(3{3-[2-tienylkarbonyl]pyrazol- [1,5-alfa]-pyrimidin-7-yl}fenyl)acetamid og blandinger ogfremgangsmåter relatert dertil
AR024963A1 (es) Oxazincarbazoles en el tratamiento de enfermedades del snc
Houlihan et al. Sleep-inducing N-alkyl-5-[m-(trifluoromethyl) phenyl]-5-hydroxy-2-pyrrolidinones and N-alkyl-3-(trifluoromethyl) cinnamamides
DE59103080D1 (de) 9-Amino-2-phenylbicyclo[3.3.1]nonane und 9-Amino-2-phenylbicyclo[3.3.1]-non-2-ene und diese enthaltende therapeutische Mittel.